Patents by Inventor Randall Schatzman

Randall Schatzman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 8992904
    Abstract: The present invention is directed to therapeutic methods and compositions, especially subcutaneous and intravenous composition using antibodies and fragments thereof having binding specificity for IL-6 to prevent or treat cachexia, fever, weakness and/or fatigue in a patient in need thereof. In preferred embodiments, the anti-IL-6 antibodies will be humanized and/or will be aglycosylated. Also, in preferred embodiments these patients will comprise those exhibiting (or at risk of developing) an elevated serum C-reactive protein level. In another preferred embodiment, the patient's survivability or quality of life will preferably be improved.
    Type: Grant
    Filed: November 24, 2010
    Date of Patent: March 31, 2015
    Assignee: Alderbio Holdings LLC
    Inventors: Jeffrey T. L. Smith, John A. Latham, Mark Litton, Randall Schatzman
  • Patent number: 8900580
    Abstract: The invention relates to the use of anti-IL-6 antibodies or antibody fragments containing a specific epitopic specificity to treat conditions involving elevated Il-6. In some embodiments the anti-IL-6 antibodies contain specific CDRs.
    Type: Grant
    Filed: November 24, 2009
    Date of Patent: December 2, 2014
    Assignee: AlderBio Holdings LLC
    Inventors: Leon Garcia-Martinez, Anne Elisabeth Carvalho Jensen, Katie Olson, Ben Dutzar, John Latham, Brian Kovacevich, Jeffrey T. L. Smith, Mark Litton, Randall Schatzman
  • Patent number: 8709756
    Abstract: Methods are provided for the synthesis and secretion of recombinant hetero-multimeric proteins in mating competent yeast. A first expression vector is transformed into a first haploid cell; and a second expression vector is transformed into a second haploid cell. The transformed haploid cells, each individually synthesizing a non-identical polypeptide, are identified and then genetically crossed or fused. The resulting diploid strains are utilized to produce and secrete fully assembled and biologically functional hetero-multimeric protein.
    Type: Grant
    Filed: August 30, 2012
    Date of Patent: April 29, 2014
    Assignees: Keck Graduate Institute, Alder Biopharmaceuticals, Inc.
    Inventors: James M. Cregg, John Latham, Mark Litton, Randall Schatzman, Ilya I. Tolstorukov
  • Publication number: 20130183293
    Abstract: The present invention is directed to therapeutic methods using antibodies and fragments thereof having binding specificity for IL-6 to prevent or treat cachexia, fever, weakness and/or fatigue in a patient in need thereof. In preferred embodiments, the anti-IL-6 antibodies will be humanized and/or will be aglycosylated. Also, in preferred embodiments these patients will comprise those exhibiting (or at risk of developing) an elevated serum C-reactive protein level. In another preferred embodiment, the patient's survivability or quality of life will preferably be improved.
    Type: Application
    Filed: November 20, 2012
    Publication date: July 18, 2013
    Applicant: ALDERBIO HOLDINGS LLC
    Inventors: Jeffrey T.L. Smith, John A. Latham, Mark Litton, Randall Schatzman
  • Publication number: 20130034554
    Abstract: The present invention is directed to therapeutic methods using IL-6 antagonists such as an Ab1 antibody or antibody fragment having binding specificity for IL-6 to prevent or treat disease or to improve survivability or quality of life of a patient in need thereof. In preferred embodiments these patients will comprise those exhibiting (or at risk of developing) an elevated serum C-reactive protein level, reduced serum albumin level, elevated D-dimer or other coagulation cascade related protein(s), cachexia, fever, weakness and/or fatigue prior to treatment. The subject therapies also may include the administration of other actives such as chemotherapeutics, anti-coagulants, statins, and others.
    Type: Application
    Filed: November 24, 2010
    Publication date: February 7, 2013
    Inventors: Leon F. Garcia-Martinez, Anne Elisabeth Carvalho Jensen, Katie Olson, Benjamin H. Dutzar, John A. Latham, Brian Robert Kovacevich, Jeffrey T.L. Smith, Mark Litton, Randall Schatzman
  • Publication number: 20130029880
    Abstract: Methods are provided for the synthesis and secretion of recombinant hetero-multimeric proteins in mating competent yeast. A first expression vector is transformed into a first haploid cell; and a second expression vector is transformed into a second haploid cell. The transformed haploid cells, each individually synthesizing a non-identical polypeptide, are identified and then genetically crossed or fused. The resulting diploid strains are utilized to produce and secrete fully assembled and biologically functional hetero-multimeric protein.
    Type: Application
    Filed: August 30, 2012
    Publication date: January 31, 2013
    Inventors: James M. Cregg, John Latham, Mark Litton, Randall Schatzman, Ilya I. Tolstorukov
  • Publication number: 20130028860
    Abstract: The present invention is directed to therapeutic methods and compositions, especially subcutaneous and intravenous composition using antibodies and fragments thereof having binding specificity for IL-6 to prevent or treat cachexia, fever, weakness and/or fatigue in a patient in need thereof. In preferred embodiments, the anti-IL-6 antibodies will be humanized and/or will be aglycosylated. Also, in preferred embodiments these patients will comprise those exhibiting (or at risk of developing) an elevated serum C-reactive protein level. In another preferred embodiment, the patient's survivability or quality of life will preferably be improved.
    Type: Application
    Filed: November 24, 2010
    Publication date: January 31, 2013
    Inventors: Jeffrey T.L. Smith, John A. Latham, Mark Litton, Randall Schatzman
  • Patent number: 8337847
    Abstract: The invention provides methods of treating anemia in patients in need thereof, particularly in patients having anemia associated with chronic and/or inflammatory conditions such as cancers and arthritic conditions by administering antibodies or antibody fragments that bind IL-6. The treatment methods result in increased hemoglobin.
    Type: Grant
    Filed: November 24, 2009
    Date of Patent: December 25, 2012
    Assignee: AlderBio Holdings LLC
    Inventors: Jeffrey T. L. Smith, John Latham, Mark Litton, Randall Schatzman
  • Patent number: 8268582
    Abstract: Methods are provided for the synthesis and secretion of recombinant hetero-multimeric proteins in mating competent yeast. A first expression vector is transformed into a first haploid cell; and a second expression vector is transformed into a second haploid cell. The transformed haploid cells, each individually synthesizing a non-identical polypeptide, are identified and then genetically crossed or fused. The resulting diploid strains are utilized to produce and secrete fully assembled and biologically functional hetero-multimeric protein.
    Type: Grant
    Filed: October 22, 2004
    Date of Patent: September 18, 2012
    Assignees: Keck Graduate Institute, Alder Biopharmaceuticals, Inc.
    Inventors: James M. Cregg, John Latham, Mark Litton, Randall Schatzman′, Ilya I. Tolstorukov
  • Publication number: 20110183402
    Abstract: Methods are provided for the synthesis and secretion of recombinant proteins preferably large mammalian proteins or hetero-multimeric proteins at high levels and for prolonged time in polyploid, preferably diploid yeast. These methods use various mating competent yeast, including Pichia. In a preferred embodiment, a first expression vector is transformed into a first haploid cell; and a second expression vector is transformed into a second haploid cell. The transformed haploid cells, each individually synthesizing a non-identical polypeptide, are identified and then genetically crossed or fused. The resulting diploid strains are utilized to produce and secrete fully assembled and biologically functional hetero-multimeric protein.
    Type: Application
    Filed: March 24, 2011
    Publication date: July 28, 2011
    Inventors: JAMES M. CREGG, JOHN LATHAM, MARK LITTON, RANDALL SCHATZMAN, IIYA I. TOLSTORUKOV
  • Patent number: 7927863
    Abstract: Methods are provided for the synthesis and secretion of recombinant proteins preferably large mammalian proteins or hetero-multimeric proteins at high levels and for prolonged time in polyploid, preferably diploid yeast. These methods use various mating competent yeast, including Pichia. In a preferred embodiment, a first expression vector is transformed into a first haploid cell; and a second expression vector is transformed into a second haploid cell. The transformed haploid cells, each individually synthesizing a non-identical polypeptide, are identified and then genetically crossed or fused. The resulting diploid strains are utilized to produce and secrete fully assembled and biologically functional hetero-multimeric protein.
    Type: Grant
    Filed: May 8, 2006
    Date of Patent: April 19, 2011
    Assignees: Alder BioPharmaceuticals, Inc., Keck Graduate Institute
    Inventors: James M. Cregg, John Latham, Mark Litton, Randall Schatzman, Ilya I. Tolstorukov
  • Publication number: 20100158859
    Abstract: The present invention is directed to therapeutic methods using antibodies and fragments thereof having binding specificity for IL-6 to prevent or treat cachexia, fever, weakness and/or fatigue in a patient in need thereof. In preferred embodiments, the anti-IL-6 antibodies will be humanized and/or will be aglycosylated. Also, in preferred embodiments these patients will comprise those exhibiting (or at risk of developing) an elevated serum C-reactive protein level. In another preferred embodiment, the patient's survivability or quality of life will preferably be improved.
    Type: Application
    Filed: November 24, 2009
    Publication date: June 24, 2010
    Inventors: Jeffrey T.L. Smith, John Latham, Mark Litton, Randall Schatzman
  • Publication number: 20100150829
    Abstract: The present invention is directed to therapeutic methods using IL-6 antagonists such as an Ab1 antibody or antibody fragment having binding specificity for IL-6 to prevent or treat disease or to improve survivability or quality of life of a patient in need thereof. In preferred embodiments these patients will comprise those exhibiting (or at risk of developing) an elevated serum C-reactive protein level, reduced serum albumin level, elevated D-dimer or other coagulation cascade related protein(s), cachexia, fever, weakness and/or fatigue prior to treatment. The subject therapies also may include the administration of other actives such as chemotherapeutics, anti-coagulants, statins, and others.
    Type: Application
    Filed: November 24, 2009
    Publication date: June 17, 2010
    Inventors: Leon Garcia-Martinez, Anne Elisabeth Carvalho Jensen, Katie Olson, Ben Dutzar, John Latham, Brian Kovacevich, Jeffrey T.L. Smith, Mark Litton, Randall Schatzman
  • Publication number: 20080003643
    Abstract: Methods are provided for the synthesis and secretion of recombinant hetero-multimeric proteins in mating competent yeast. A first expression vector is transformed into a first haploid cell; and a second expression vector is transformed into a second haploid cell. The transformed haploid cells, each individually synthesizing a non-identical polypeptide, are identified and then genetically crossed or fused. The resulting diploid strains are utilized to produce and secrete fully assembled and biologically functional hetero-multimeric protein.
    Type: Application
    Filed: October 22, 2004
    Publication date: January 3, 2008
    Inventors: James M. Cregg, John Latham, Mark Litton, Randall Schatzman, Ilya I. Tolstorukov
  • Publication number: 20060270045
    Abstract: Methods are provided for the synthesis and secretion of recombinant proteins preferably large mammalian proteins or hetero-multimeric proteins at high levels and for prolonged time in polyploid, preferably diploid yeast. These methods use various mating competent yeast, including Pichia. In a preferred embodiment, a first expression vector is transformed into a first haploid cell; and a second expression vector is transformed into a second haploid cell. The transformed haploid cells, each individually synthesizing a non-identical polypeptide, are identified and then genetically crossed or fused. The resulting diploid strains are utilized to produce and secrete fully assembled and biologically functional hetero-multimeric protein.
    Type: Application
    Filed: May 8, 2006
    Publication date: November 30, 2006
    Applicants: Keck Graduate Institute, Alder Biopharmaceuticals, Inc.
    Inventors: James Cregg, John Latham, Mark Litton, Randall Schatzman, Ilya Tolstorukov
  • Publication number: 20050282754
    Abstract: The present invention relates to peptides and peptide analogues designed from HFE protein. In particular, it relates to peptides and peptide analogues designed from an alpha-1 region of HFE protein which lowers the binding affinity of transferrin receptor for transferrin. Such compounds mimic HFE protein function, and reduce iron uptake and/or accumulation by a cell.
    Type: Application
    Filed: July 18, 2005
    Publication date: December 22, 2005
    Inventors: John Feder, Randall Schatzman, Pamela Bjorkman, Melanie Bennett, Jose Lebron
  • Publication number: 20050090430
    Abstract: Methods and compositions are provided for the diagnosis and treatment of iron misregulation diseases, including HFE polypeptides, agonists, and antagonists, and transferrin receptor agonists and antagonists.
    Type: Application
    Filed: October 1, 2004
    Publication date: April 28, 2005
    Inventors: John Feder, Randall Schatzman, Zenta Tsuchihashi